|
Research InterestsProfessor Ric Day | | (Position Details) | | Phone 02 8382 2331 | | Email | | Qualifications AM, MB BS Syd, MD UNSW, FRACP |
| | | School/Unit |
| St Vincent's Clinical School | | http://medicalsciences.med.unsw.edu.au/somsweb.nsf/page/about%20pharmacology
| |
| | Broad Research Areas | |
|
Preventive Medicine
Pharmacology
Pain
Diabetes
Arthritis / Rheumatology
| |
| | | | Specific Research Keywords | |
| Rheumatology
Gout
Drug Safety
Clinical Pharmacology
Diabetes and Endocrinology
| |
| | | | Research Interests | |
| Rheumatic disorders and Diabetes are prevalent chronic illnesses that demand high quality pharmacotherapy. We are researching powerful techniques for individualising pharmacotherapy using pharmacokinetic/pharmacodynamic models. Our aim is safe yet effective therapy. Allopurinol used in gout and metformin used in diabetes are currently being studied. Also we are investigating the mechanisms of paracetamol actions. We are examining genetic factors that predict serious adverse drug reactions and explain variation in response to medicines. The effects of electronic medication management in a teaching hospital on the rate of adverse events occurring is a new research interest.
| |
| | | | ILP Research Interests (Will supervise ILP students) |
| Adverse Effects
Advertising
Anti-Inflammatory Agents
Complementary Medicines
Diabetes Mellitus
Errors
Low Back Pain
Metabolic Diseases
Musculoskeletal Diseases
Osteoarthritis
Pharmaceutical Benefits
Pharmacokinetics
Pharmacology
| |
| | | | Project Topics for current Honours Students |
| 1) Metformin pharmacokinetics and pharmacodynamics: optimising dosing in individuals (2009)
2) Allopurinol hypersensitivity Syndrome: HLA associations (2008) | |
| | | | Teaching Interests | |
| Particular interest and research brief is to communicate the principles of "Quality of Use of Medicines" and to assist students to become sound and safe "Therapeuticians". This is a challenging time for graduates because of the increasing potency and precision of new drugs in a rapidly ageing world. A 'principle' base and framework is critical to allow a life-time of learning to occur in therapeutics. Innovative and broad exposure to the complex world of Therapeutics and Medicines is being incorporated in the new curriculum for medical students at UNSW. | |
| | | | Society Memberships & Professional Activities | |
| Fellow Royal Australian College of Physicians
Immediate past Chair Federal PHARM Committee (Pharmaceutical Health and Rational Use of Medicines Committee)
Member of Australian Rheumatology Association (and its Therapeutics Commitee) and Australasian Society of Clinical & Experimental Pharmacologists and Toxicologists (Past President)
Practising Clinical Pharmacologist & Rheumatologist at St Vincent's Hospital Sydney and St Vincent's Medical Centre, Darlinghurst
Director of Clinical Pharmacology & Toxicology, St Vincent's Hospital
Director of Therapeutics Centre, St Vincent's Hospital
Ex Director of the Drug Information Association | |
| | | | Funding Sources | |
| NH&MRC (5 grants as Chief Investigator); 5 year Programme Grant (2009-2013) focussed on 'Safety' with a focus on medication safety
UNSW Goldstar Grants
Arthritis Foundation Grants
St Vincent's Private Hospital Clinical Research Funds
Pharmaceutical Industry Clinical Trials | |
| | | | Other Postgraduate Research | |
|
1. PhD thesis USydney on the interactions of allopurinol and probenecid, medicines used to lower plasma uric acid in gout sufferers.
2. Pharmacoepidemiology studies of the medicines used to treat gout - Independent Learning Projects for Medical students of UNSW or Honours projects
3. Establishing improved treatment algorithms for the treatment of patients with gout - honours/PhD projects
4 Decision support tools for selecting the correct dose for medicines with low therapeutic indices eg allopurinol, metformin
5. Identification of individuals at particular risk for serious adverse drug reactions: genetic associations
6. Effectiveness of electronic medication management to reduce adverse medication related events
7. Engagement of big pharma with quality of use of medicines (ILP project)
8. Access to high cost medicines via the Pharmaceutical Benefits Scheme (recent PhD project)
9. Direct to Consumer Advertising of Medicines: Policy evaluation (with Centre for Law and Ethics USyd)
10. Optimal dosing of metformin in diabetes with focus on renal impairment (PhD projects) | |
| | | | Key works/Publications | |
| Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, Weaver A. (2000) "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis" New Engl J Med. 343(21):1520-1528
Day R. Morrison B. Luza A. Castaneda O. Strusberg A. Nahir M. Helgetveit KB. Kress B. Daniels B. Bolognese J. Krupa D. Seidenberg B. Ehrich E. (2000) "A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis" Archives of Internal Medicine 160:1781-1787
Day RO, Quinn D, Williams K, Handel M, Brooks P. Rheumatic Disorders. (2000) In Melmon & Morelli's Textbook of Clinical Pharmacology, Edition 4. Eds S. George Caruthers, B.Hoffman, K.Melmon, D Nierenberg, pp. 645-702, McGraw Hill.
P132 Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects British Journal of Clinical Pharmacology 2005; 59(4):425-432
P133 Kerridge I, Maguire D, Newby D, McNeill PM, Henry D, Hill S, Day R, MacDonald G, Stokes B, Henderson K. Cooperative partnerships or conflicts of interest? A national survey of interactions between the pharmaceutical industry and medical organizations. Internal Medicine Journal 2005; 35:206-210
P134 Henry D, Kerridge I, Hill S, McNeill PM, Doran E, Newby D, Henderson K, Maguire D, Stokes B, MacDonald G, Day R. Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience. Med J Aust 2005;182(11):557-60
P135 Hamama AK, Ray J, Day RO, Brien JE. Simultaneous Determination of Rofecoxib and Celecoxib in Human Plasma by High Performance Liquid Chromatography Journal of Chromatographic Science 2005;43:1-4
P136 Kaye KI, Welch SA, Graudins LV, Graudins A, Rotem T, Davis SR, Day RO
Pethidine in emergency departments: promoting evidence-based prescribing
Med J Aust 2005; 183 (3):129-133
P.137 Hancock MJ, Maher CG, Latimer J, Andrew J McLachlan , Cooper CW , Day RO, Spindler MF, McAuley JH. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomised controlled trial. BMC Musculoskeletal Disorders 2005, 6:57
P138 Ritchie J, Lu C, Williams K, Day R. Sample size is beside the point in policy development research. Australian & New Zealand Journal of Public Health 2005, 29, no. 6, 583 (letter)
P139 Henry D, Doran E, Hill S, McNeill PM, Day R. Ties that bind. Multiple relationships between clinical researchers and the pharmaceutical industry. Arch.Int.Med. 2005, 165;2493-6
P140 Lu CY, Ritchie J, Williams KM, Day RO. Recent developments in targeting access to high cost medicines in Australia Australia and New Zealand Health Policy 2005, 2:28 (http://www.anzhealthpolicy.com/content/2/1/28)
P141 Tan EL, Brien JE, Day RO. Perspectives on Drug and Therapeutics Committee policy implementation. Res Soc Admin Pharm 2005; 1(4):526-545.
P142 Lu CY, Williams KM, Day RO Access to tumour necrosis factor inhibitors for rheumatoid
arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target? Internal Medicine Journal 2006; 36:19–27
P143 Strand V, Conaghan P, Lohmander S, Koutsoukos AD, Hurley FL, Bird H, Brooks P, Day RO, Puhl W, Band PA. An integrated analysis of five double-blind, randomized, controlled trials evaluating the safety and efficacy of a hyaluronan product for intraarticular injection in osteoarthritis of the knee. Osteoarthritis & Cartilage 2006: 14(9):859-66, 2006 Sep.
P144 Loboz K, Gross A, Liauw W, Williams K, Day R, McLachlan A. CYP2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampicin and ethnicity. Clinical Pharmacology & Therapeutics 2006; 80:75-84
P145 Granot R, Day R, Cohen M, Murnion B, Garrick R. Targetted pharmacotherapy of evoked phenomena in neuropathic pain. A review of the current evidence. Pain Medicine 2006. 2007; 8(1):48-64
P146 McNeill PM, Kerridge IH, Henry DA, Stokes B, Hill SR, Newby D, Macdonald GJ, Day RO, Maguire, Henderson KM. Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia. Internal Medicine Journal 2006; 36:1–8
P147 Coiera E, Magrabi F, Westbrook JI, Kidd MR. Day RO. Protocol for the Quick Clinical study: a randomised controlled trial to assess the impact of an online evidence retrieval system on decision-making in general practice [ISRCTN03597773] BMC Medical Informatics and Decision Making 2006, 6:33 MS: 1491764364108785
P148 McNeill P, Kerridge I, Day R. Gifts, Drug Samples, and other items given to medical specialists by pharmaceutical companies. Bioethical enquiry 2006; 3:139-148
P149 Pearson S-A, Ringland C, Kelman C, Mant A, Lowinger J, Stark H, Nicol G, Day R, Henry D. Patterns of analgesic and anti-inflammatory medicine use by Australian veterans Internal Medicine Journal. 2007; 37:798-805
P150 Tan EL, Day RO, Brien JE. Prioritizing Drug and Therapeutic Committee (DTC) Decisions: A national survey. Pharm World Sci. 2007. DOI 10.1007/s11096-006-9074-y
P151 Lu CY, Williams KM, Day RO The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines
Australia and New Zealand Health Policy 2007, 4:2 (01 Mar 2007)
P152 Murnion B, Granot R, Day RO. Utility of urine drug screening: A Clinical Audit. Emergency Medicine Australasia 2007; 19:246-252
P153 Lu CY, Williams KM, Day RO. Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme? Internal Medicine Journal 2007; 37:601-606
P154 Stocker SL, Williams KM, McLachlan AJ, Graham GG, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Clinical Pharmacokinetics 2008; Accepted for publication.
P155 Hancock M, Maher C, Latimer J, McLachlan A, Cooper C, Day R, et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial. Lancet 2007;370:1638-1643.
P156 Xu H, Williams KM, Liauw WS, Murray M, Day RO, McLachlan AJ. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. British J Pharmacology 2008; 153(7):1579-1586
P157 Stocker SL, Williams KM, McLachlan AJ, Graham GG, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Clinical Pharmacokinetics 2008; 47 (2): 111-118
P158 Chung Y, Lu C, Graham GG, Mant A, Day R. Utilisation of allopurinol in the Australian community. Internal Medicine Journal 2008; 38(6):388-95.
P159 Magrabi F, Westbrook JI, Kidd M, Day R, Coiera E (2007) Long term patterns of online evidence retrieval use in general practice: a 12-month study. Journal of Medical Internet Research. 2008; 10(1):art. No. e6 (selected for publication in the 2009 IMIA Yearbook of Medical Informatics)
P160 Mohamed Abdul MI, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, Xu H, McLachlan AJ, Pharmacodynamic interaction of Warfarin with Cranberry but not with Garlic in Healthy Subjects”. British J Pharmacology 2008; 154 (8):1691-1700 [IF:
P161 Lu CY, McNeill P, Williams K, Day RO. Access to high cost medicines in Australia: ethical perspectives. Australia & New Zealand Health Policy 5:4 doi:10.1186/1743-8462-5-4
Reviews
R158 Graham GG, Scott KF, Day RO. Tolerability of paracetamol. Drug Safety 2005; 28:227-240
R159 Day RO, Furst DE, van Riel PLCM, Bresnihan B. (Editors). Antirheumatic Therapy: Actions and Outcomes. In Progress in Inflammation Research. Editor. Michael J Parnham. Burkhauser Verlag, Basel, 2005
R160 Day RO, Graham GG. Paracetamol should be first line therapy in osteoarthritis (letter). Medical J Australia 2005; 182:198-9
R161 Day RO, Birkett DJ, Miners J, Shenfield GM, Henry DA, Seale JP. Access to medicines and high-quality therapeutics: global responsibilities for clinical pharmacology. Medical J Australia 2005; 322-3
R162 Bachmeier C, Brooks PM, Day RO, Conaghan PG, Graham GG, Littlejohn GO, Morand E, Pile K,. Williams KM,. Disease Modifying Antirheumatic Drugs. In Principles of Immunopharmacology, eds FP Nijkamp & MJ Parnham 2005, pp 511-544, Burkhauser.
R163 Lassere MN, Johnson K, Woodworth T, Furst DE, Fries J, Kirwan J, Tugwell P, Day RO, Brooks PM. Challenges and progress in adverse event ascertainment and reporting in clinical trials J Rheumatology 2005; 32(10):2030 – 2032
R164 Lu C, Williams KM, Day RO. Accessing health outcomes data on high-cost medicines in Australia. Med J Aust 2006; 184(8):411-3
R165 Day RO, March LM, Graham GG, Scott KF, Williams KM. NSAIDs and analgesics. In: Rheumatoid Arthitis, 2nd Edition,. Eds Gary S Firestein, Gabriel S Panayi, Frank A. Wollheim 2006, pp 317-336, Oxford University Press.
R166 Kaye KI, Lu CY, Day RO. Can we deny patients expensive drugs? Australian Prescriber 2006; 29(6):146-148
R167 Day Richard O, Graham Garry G. NSAIDS and their indications. In: Encyclopedia of Pain. Eds Robert F. Schmidt & William D. Wallis. 2007. http://www.springerlink.com/content/1w8x117774111117/fulltext; Springer-Verlag Berlin Heidelberg 2007, 10.1007/978-3-540-29805-2_2847
R168 Day RO, Williams KM. Open-Label Extension Studies. Do They Provide Meaningful Information on the Safety of New Drugs? Drug Safety 2007: 30 (2): 93-105
R169 Kelman CW, Pearson SA, Day RO, Holman CDJ, Kliewer EV, Henry D. Evaluating medicines: let’s use all the evidence. Medical J Australia 2007; 186(5):249-252
R170 Day RO, Graham GG, Williams KM. Fenofibrate-warfarin interaction (Letter). Australian Prescriber 2007;30:32-4
R.171 Day R, Lu CY, Pearce G, Grainger D. Pharmaceutical Benefits Scheme: Rapid change and impetus towards achieving QUM. J Pharmacy Practice and Research 2007; 37(1):4-6
R172 Kaye K, Lu C, Day R. Can we deny patients expensive drugs (comment). Australian Prescriber 2007; 30(3):60
R173 Graham GG, Day R. Paracetamol (expert comment). Australian Prescriber 2007; 30(3):61
R174 Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clinical Pharmacokinetics 2007; 46(8):623-644
R175 Chung Y, Stocker S, Graham G, Day RO. Optimising therapy with allopurinol: Factors limiting hypouricaemic efficacy. American Journal of Medical Sciences 2008; 335 (3):219-226.
R176 Miners JO, Day RO Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymes British Journal Of Clinical Pharmacology 2007; 63 (3): 380-381 MAR
R178 Lu C, Williams K, Day R. Access to biologic medicines for the treatment of rheumatic diseases: lessons from Australia. International Journal of Rheumatology 2008; 11:11-14
R179 Lee H, Graham G, Williams K, Day R. A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout. Drug Safety 2008; 31(8):643-665 [IF:]
R 180 McLachlan, A., Day, R., Williams, K., Graham, G., Stocker, S. Maximising gout therapy Australian Journal of Pharmacy 2008, 89 (1057) pp. 86-88.
R 181 Day RO, Fransen M. Osteoarthritis: NSAIDs, paracetamol or other treatment approaches. Medicine Today 2008; 9(10):71-76 | |
| | | | Attachments | |
|
Full Papers.RDay.06 | |
| | | | Further Information | |
| | |
Profile last updated: 14/04/2009 Need to update your profile? Login to your profile with your Staff ID, prefixed by a lower case "s" or "z" (eg s1234567 or z1234567), and UniPass to update your profile. If you have any problems please send an email to .
|
|